The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults. The drug is the first FDA-approved treatment for this condition that is not an antipsychotic. FDA initially approved Auvelity in 2022 to treat major depressive disorder in adults.
Read more HERE
Drugs once hailed as a breakthrough in the fight against Alzheimer’s disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.
The review by the Cochrane organization – which is considered the gold standard for analyzing existing evidence – looked at drugs that target a plaque called amyloids, which builds up in the brains of Alzheimer’s patients.
Read more HERE
Alzheimer; News from the web:
There is no cure for Alzheimer’s disease, but medication can help manage the condition. Currently, the main drugs used to treat Alzheimer’s are what’s known as symptomatic therapies, meaning they ease symptoms but don’t address the cause of the disease. These include cholinesterase inhibitors and memantine. A more recent entry into the field, lecanemab, may help slow the progression of the disease. Here’s a look at how these medications work.
Read all about it HERE
Alzheimer; News from the web:
Read all about it HERE
Alzheimer; News from the web:
WASHINGTON — Medicare’s “Part B” outpatient premium will jump by $21.60 a month in 2022, one of the largest increases ever. Officials said Friday a new Alzheimer’s drug is responsible for about half of that.
Read all about it HERE
Alzheimer; News from the web:
The results of the clinical studies submitted by the drug’s manufacturer, Biogen, and the FDA’s accelerated approval, have been highly criticized by experts in the field.
Read all about it HERE